Advanced Trauma & Hemorrhage Care Through Bespoke Research

An International Multidisciplinary Military and Civilian Network

The THOR Research Institute (TRI), an LLC and subsidiary of THOR Network Foundation, is comprised of investigators spanning the full translational research pipeline, from basic science to clinical trials to implementation science. Advancing trauma and hemorrhage care through bespoke research designed for impact, TRI shapes studies around the urgent challenges of bleeding control, resuscitation, and survival in real-world settings.

Submit a Request for Proposal

Submit a Request for Proposal (RFP) for research or educational projects via the following link.

Click Here

Capabilities & Services

  • Program/project management
  • CMC & quality systems
  • Pre-clinical product or device development planning
  • Marketing surveys
  • Customizable approach to trial development and implementation
  • Phase 1–4 trial development experience
  • Clinical Coordination Center Capabilities:
    • Site selection document production
    • Regulatory Management
    • Trial Execution
  • DCC Capabilities:
    • Data management
    • Staistical design and analyses
    • Generic DCC service description three
    • Generic DCC service description four
  • FDA & global authority experience
  • IND/NDA/BLA authoring
  • Expert consulting for industry/government engagement
  • Scientific Advisory Board development
  • Scientific webinar series development and execution
  • Product/Device beta testing with analysis and feedback

Clinical Trials Experience

THOR Research Institute (TRI) leads and collaborates on a range of clinical, laboratory, and educational studies advancing transfusion medicine and trauma care. Our team partners with federal agencies, academic centers, and industry to translate discovery into practice. TRI leaders have designed and executed some of the seminal trials in trauma and transfusion medicine such as ABC-PICU, TAMPITI, CHIPS, MATIC-2. We specialize in adaptive trial designs with Bayesian Analyses when appropriate.

The below trials are a sample of previously performed, current and in-progress clinical trials led by TRI leadership.

ABC-PICU

Phase 3 | FDA Regulated-IND Required | Completed | (NCT01977547) | Published (PMID 31821429) Age of Blood in Children in Pediatric Intensive Care Units. 1500 patients at 50 centers internationally.

Learn More

TAMPITI Trial

Phase 2 | FDA Regulated-Exception to Informed Consent | Completed | Published (PMID 33013880) Examining the immunologic effects of TXA in adults with severe bleeding from traumatic injury. 150 patients at one trial site.

Learn More

CHIPS Trial

Phase 3 | FDA-Regulated-IND Required | Completed | Global (NCT04834414) Evaluating safety and efficacy of cold stored platelets in cardiac surgery patients. 1,000 patients at 24 sites internationally.

Learn More

MATIC-2 Trial

MATIC-2 Trial Phase 3 | FDA-Regulated-Exception to Informed Consent | Enrolling | (NCT06070350) Adaptive platform trial, comparing whole blood vs component therapy and TXA vs placebo in 1,000 pediatric trauma patients. Planned enrollment of 1,000 patients at 24 trial sites.

Learn More

Fibrinogen in Liver Transplant Study (FITS)

Phase 2 | TRl-Sponsor with Industry Support| Enrolling | (NCT06764927) Preliminary study to inform the effect size of a definitive trial comparing Intercept Fibrinogen Complex to cryoprecipitate in liver transplant patients with reduced fibrinogen function.

Learn More

Randomized Control Study in REsuscitation of SEpsis Trial (RESET)

Phase 2 | Industry Sponsored | Randomized Controlled Trial | Enrolling (NCT07035509) Assessing efficacy and safety of plasma vs crystalloids for volume resuscitation in children with septic shock. Single site with plan to enroll up to 150 patients.

Learn More

Trials in Development

Advancing Transfusion Care in Cancer

Patients with hematologic cancers and those undergoing chemotherapy or stem-cell transplantation often develop thrombocytopenia–dangerously low platelet counts that increase the risk of bleeding. As a result, cancer care represents one of the largest areas of platelet transfusion use.

Hematology-Oncology Research

Plasma Resuscitation in Septic Shock (PRESS)

Patients with hematologic cancers and those undergoing chemotherapy or stem-cell transplantation often develop thrombocytopenia–dangerously low platelet counts that increase the risk of bleeding. As a result, cancer care represents one of the largest areas of platelet transfusion use.

Research Institute Directors

Philip C. Spinella

President, THOR Research Institute

Read Bio

Elon Glassberg

Manager, THOR Research Institute

Read Bio

Taegen Sullivan

Co-Director, THOR Research Institute

Read Bio

Bettina Bockelmann

Co-Director & Secretary, THOR Research Institute

Read Bio

Affiliate Investigators

  • Mark Yazer MD – Bio
  • Travis Polk MD, FACS – Bio
  • Matthew D. Neal MD, FACS – Bio
  • Michael Reade – Bio
  • Christian Kastrup PhD – Bio
  • Elissa Milford – Bio
  • Dr Angelo D’Alessandro, PhD – Bio
  • Andrew Beckett, CD, MD, MSc, FRCSC, FACS – Bio
  • Anirban Sen Gupta, PhD – Bio
  • Bethany Brown – Bio
  • Bryan Cotton, MD, MPH, FACS – Bio
  • Thomas Scorer, MD – Bio
  • James Preuss – Bio
  • Moritz Stolla, M.D. AB+ – Bio
  • Susanne Marschner – Bio
  • COL Jennifer Gurney, MD – Bio
  • Fabrizio Chiusolo MD – Bio
  • Jeremy Cannon
  • Tom Woolley